The purpose of this study is to evaluate the safety and preliminary efficacy of BMS-986393 (CC-95266) in participants with relapsed and/or refractory multiple myeloma (R/R MM).
SparkCures ID | 1151 |
---|---|
Trial Phase | Phase 1 |
Enrollment | 75 Patients |
Treatments | |
Tags | |
Trial Sponsors |
|
NCT Identifier |
|
The following criteria is a partial list of reasons why patients may or may not be eligible to participate in this clinical trial. Further evaluation with a medical professional will be required to determine full eligibility.
The following criteria is provided for health care professionals.
Inclusion Criteria:
Exclusion Criteria:
Please visit the ClinicalTrials.gov page for historical site information.
View CentersSparkCures is working closely with Juno Therapeutics, a Bristol-Myers Squibb Company to provide the most up-to-date information on this clinical trial. Use the button above to add this trial to your list of favorites.
Learn more about how we work with trial sponsors